GI-301 is under clinical development by Yuhan and currently in Phase I for Allergic Asthma. According to GlobalData, Phase I drugs for Allergic Asthma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GI-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GI-301 overview
GI-301 is under development for chronic idiopathic urticarial (CIU), atopic dermatitis, allergic asthma and food allergy. The drug candidate is being developed based on GI-SMART platform technology. It is administered through subcutaneous route.
Yuhan overview
Yuhan discovers, develops, manufactures and markets pharmaceutical products. The company offers APIs and intermediates for antibiotic, antiviral, antifungal, anti-thrombotic, anti-inflammatory, anti-diabetic and anti-hyperlipidemics. The company offers finished goods for the treatment of hypertension, coronary artery disease, hyperlipidemia, cerebral thrombosis and other diseases. Yuhan provides custom synthesis services for other pharmaceutical and biopharmaceutical companies. It offers active pharmaceutical ingredients (API) and finished products in domestic as well as international market. Yuhan operates R&D and manufacturing facilities in Seoul. The company offers its products and services through its sales and distribution branches. Yuhan is headquartered in Seoul, South Korea.
For a complete picture of GI-301’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
